ResMed Appoints New South Asia General Manager to Help Drive Increased Awareness & Treatment of Sleep Apnea, Other Respirator...
May 30 2019 - 12:30AM
Business Wire
Ms. Shubhi Khurana will oversee business
operations in India and South Asia
ResMed, a world leader in connected health solutions for sleep
apnea, lung disease, and other chronic diseases, today announced
the appointment of Shubhi Khurana as general manager for India and
South Asia.
Ms. Khurana, former general manager of Capsugel India Region
(now Lonza), oversees business operations including setting
strategic priorities, evolving team and go-to-market models for
ResMed’s long-term growth. She aims to enhance ResMed’s leadership
in the region by enabling efforts in developing innovative
technology-enabled care pathways and improving patients’ therapy
experiences.
These initiatives also encompass market development and
awareness measures to educate the public, medical community, and
decision makers about the prevalence of sleep and respiratory
diseases in South Asia, as well as how to diagnose and treat them
at home with cloud-connectable non-invasive devices. These
campaigns support efforts to address the under-penetration of sleep
and respiratory care markets in India and neighboring countries,
and help millions of people improve their quality of life.
An estimated 52 million Indians have sleep apnea – the vast
majority are undiagnosed – and 55 million have COPD (chronic
obstructive pulmonary disease), the fourth leading cause of death
annually worldwide, according to the World Health Organization.
“Sleep apnea and COPD are global health epidemics and are
especially prevalent in Asia,” said Justin Leong, president of
ResMed’s Asia Growth Markets. “In India, these diseases are highly
underdiagnosed due to low awareness amongst both doctors and the
general community. Given the link between these diseases, and other
chronic diseases like diabetes, hypertension, stroke, cognitive
disorders and cancer, it is critical we continue to educate and
treat people with these conditions. We are thrilled to have Shubhi
join us at this important time.”
“I am excited to accept this critical role,” said Ms. Khurana,
“and to grow both public awareness of the health epidemics ResMed
helps treat and ResMed’s own reputation as an important digital
health leader in this space. Research on the impacts of sleep apnea
and COPD are only a few decades old. Therefore, the potential to
make an impact in people lives and their health through ResMed’s
innovative offerings is a great opportunity in itself.”
Ms. Khurana has more than two decades of experience in the
pharmaceutical, healthcare, and medtech industries in various
leadership roles. Before Capsugel, she worked at Baxter and Baxalta
(now Takeda), building their Critical Care, Rare Diseases, and
Surgical Kits business.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit
ResMed.com and follow @ResMed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190529006028/en/
For mediaPallavi Kumari+91 9205289833news@resmed.com
For investorsAmy Wakeham+1
858.836.5000investorrelations@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024